 steadi drug divis help mitig pressur
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
johnson johnson stand alon leader across major
base develop research pipelin except cash flow
gener togeth creat wide econom moat
 hold leadership role divers healthcar segment
includ medic devic over-the-count product sever
pharmaceut market contribut total
revenu pharmaceut divis boast sever industry-lead
drug includ immunolog drug remicad psoriasi drug
stelara medic devic group bring one third
sale compani hold control posit mani
area includ orthoped ethicon endo-surgeri surgic
devic consum divis larg round remain
busi line despit manufactur issu past
sever year group still hold mani brand strong price
research develop effort result next-gener
product pharmaceut group recent launch sever
new blockbust howev rel compani size
need increas number meaning drug late-stag
develop support long-term growth compani also
creat new medic devic includ ceram orthoped
expenditur sale strong cash gener
enabl firm increas dividend past half
centuri expect continu also allow take
advantag acquisit opportun augment growth
divers oper segment coupl expect new product
insul compani patent loss rel
pharma firm contrast peer face
major near-term patent loss hard-to-mak
complex drug like slow gener competit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
johnson johnson world largest divers healthcar
compani three divis make firm pharmaceut medic devic
diagnost consum drug devic group repres close
sale drive major cash flow firm close
half total revenu gener within unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
led robust drug sale johnson johnson post
solid lead rais fve jan
johnson johnson report fourth-quart result
ahead consensu expect
plan slightli increas fair valu estim base
better-than-expect result solid perform
drug unit oper exclud acquisit
divestitur combin steadi growth
devic segment help mitig flat growth
consum arm intellectual-properti moat
sourc around drug group switching-cost moat
sourc devic look solid secur compani wide
moat continu weak consum group
signal erod brand power believ increas
internet use purchas consum good weigh
firm brand power compani hasnt optim
market messag distribut channel similar
trend seen pharma consum unit
turn strength quarter drug unit continu
post gain led immunolog drug stelara well
cancer drug imbruvica darzalex zytiga expect
growth slow drug next year
stelara new indic crohn diseas drive
sale expect new competit psoriasi slow
drug total growth oncolog imbruvica darzalex look
well-posit growth cll multipl myeloma
respect target patient popul grow
base expect success outcom new studi
howev expect zytiga face gener competit
octob js largest drug remicad expect
acceler quarterli declin biosimilar
competit intensifi year
tax front took billion one-tim charg
due new tax law expect new tax law
help compani lower tax rate basi
point increas flexibl use oversea cash
howev given recent larg acquisit actelion
dont expect major acquisit compani near
complet overview compani posit
immunolog oncolog cardiolog well deep
dive compani pipelin pleas see healthcar
secur pharma moat
valuat growth profit jan
increas fair valu estim per share
base improv outlook overal margin
partli due better tax save origin
project within core driver cash flow new
immunolog oncolog drug drive growth
includ actelion acquisit expect annual
earn per share growth averag next
five year strong growth new pipelin drug
off-set patent loss pharmaceut divis
near term result actelion acquisit
bring high-margin drug also expect wane
cost-remedi effort consum group
increas cost-contain effort throughout firm
help off-set margin pressur due loss patent
protect sever high-margin drug
larg basi low volatil cash flow
divers inelast product portfolio rate johnson
 johnson uncertainti low scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show minor varianc
henc low fair valu uncertainti rate key factor
affect scenario analysi includ degre
success drug pipelin along magnitud
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
group consum product repres
total sale respect addit within
segment one product domin sale lipitor
despit carri lower-margin divis
maintain strong price power post gross
margin past five year valid
strong competit posit
johnson johnson effort support robust revenu
base pharmaceut compani recent launch
sever new blockbust allow johnson
johnson escap larg unscath upcom patent
expir effort medic devic includ
minim invas surgic tool help maintain
leadership sever medic devic area well
remain high sever devic product
exampl physician switch vendor hip knee
devic could take week month learn new
product keep physician tie compani
consum side new product
advanc combin strong brand power
reinforc market campaign sustain solid
compani face manag patent loss next
year price power core franchis
rel stabl turn macro environ
compani face sever headwind make solid
strateg move address challeng neg
side risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
pharmaci benefit manag consolid past
decad use grow size demand
lower drug price reduc coverag less innov
drug forc drug firm push true innov
market pressur current market drug
importantli potenti pressur remicad
biosimilar unknown regulatori impact on-going
litig surround devic also weigh certainti
believ johnson johnson carri one widest
moat healthcar sector support intellectu
properti drug group switch cost devic
segment strong brand power consum group
compani divers revenu base strong pipelin
robust cash flow gener creat wide econom
candid smaller biotechnolog compani look
partner new drug strengthen johnson
johnson abil bring new product market
johnson johnson divers oper major pillar
support wide moat compani hold leadership
role number segment includ medic devic
over-the-counter medicin sever drug market
compani overli depend one particular oper
segment pharmaceut busi medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reduc power compani distribut network
 govern evalu compar
effect program aggress price
negoti rais bar futur innov
johnson johnson face sever headwind pipelin
focus innov treatment area unmet
medic area oncolog immunolog
payer coverag price power remain strong outsid
pipelin strong entrench medic devic
consum good give firm relief
pressur pharmaceut group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth major near-term patent loss
product hard manufactur includ
biolog drug remicad limit gener
oproduct litig manufactur issu
power brand name segment brand
recognit import
odivers healthcar segment help insul
downturn economi offer defens
growth opportun steadi like grow
osever johnson johnson key drug
pipelin drug specialti drug tend carri
strong price power well lower regulatori
hurdl approv
oleg action regard product recal hip knee
replac along sever consum product
could damag compani brand power cost
billion dollar creat distract
osever johnson johnson import drug
face increas competit could slow
growth rate drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
johnson johnson hold one strongest financi
posit healthcar sector recent acquisit
actelion put dent compani cash balanc
annual free cash flow approach billion
compani sound financi shape even expect
bolt-on acquisit share repurchas
compani remain solid financi foot
oper standpoint patent loss mitig sever
divers oper line medic devic consum
product cash flow remain rel stabl
addit expect share repurchas next
sever year draw share count
johnson johnson need overcom sever roadblock
system drug risperd surgic mesh product
metal-on-met hip knee implant sever product
recal could damag sterl reput
longer term compani face typic healthcar risk
reduc price power govern
pharmaci benefit manag regulatori delay
nonapprov well increasingli aggress gener
competit small-molecul drug biolog
particular biosimilar risk remicad increas
sever biosimilar work gain market share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
overal view stewardship johnson johnson
rel standard firm good record
make sound capit deploy decis
consist gener return invest capit
cost capit major recal recent potenti
overpay actelion poor turnaround time
address manufactur problem certain key divis
lead us balanc view compani
weldon step top posit
lead johnson johnson sinc given
weldon age rigor process find successor
see chang leadership red flag gorski
bring strong record industri experi date back
began industri pharmaceut
johnson johnson
subsequ advanc mani manag
posit drug devic divis johnson
johnson along manageri post novarti give
broad experi need run massiv health
conglomer first major test gorski leadership
billion acquisit orthoped devic firm
synth larg driven gorski head
johnson johnson devic unit believ
acquisit ad import exposur emerg market
trauma devic appear small
impact valuat price paid synth larg
account
increment benefit gain
acquisit second major test gorski recent
complet actelion deal skeptic
abl creat much valu sharehold due high
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
led robust drug sale johnson johnson post
solid lead rais fve jan
johnson johnson report fourth-quart result
ahead consensu expect
plan slightli increas fair valu estim base
better-than-expect result solid perform
drug unit oper exclud acquisit
divestitur combin steadi growth
devic segment help mitig flat growth
consum arm intellectual-properti moat
sourc around drug group switching-cost moat
sourc devic look solid secur compani wide
moat continu weak consum group
signal erod brand power believ increas
internet use purchas consum good weigh
firm brand power compani hasnt optim
market messag distribut channel similar
trend seen pharma consum unit
turn strength quarter drug unit continu
post gain led immunolog drug stelara well
cancer drug imbruvica darzalex zytiga expect
growth slow drug next year
stelara new indic crohn diseas drive
sale expect new competit psoriasi slow
drug total growth oncolog imbruvica darzalex look
well-posit growth cll multipl myeloma
respect target patient popul grow
base expect success outcom new studi
howev expect zytiga face gener competit
octob js largest drug remicad expect
acceler quarterli declin biosimilar
competit intensifi year
tax front took billion one-tim charg
due new tax law expect new tax law
help compani lower tax rate basi
point increas flexibl use oversea cash
howev given recent larg acquisit actelion
dont expect major acquisit compani near
complet overview compani posit
immunolog oncolog cardiolog well deep
dive compani pipelin pleas see healthcar
secur pharma moat
fleshed-out hous tax reform support mani
dont intend make signific revis tax
reform assumpt follow hous committe
way mean releas tax cut job act
first document actual detail tax reform
may work adjust polit constitu
digest attend polit realiti slim
republican major senat taken account
continu believ tax reform trump
administr like occur
tax reform assumpt weve incorpor
valuat reason approxim potenti
outcom realm corpor tax reform bill
touch mani area previous opin
upon corpor tax rate depreci interest
expens treatment foreign earn tax credit
therefor dont plan make chang
econom moat rate fair valu estim
today releas continu monitor situat
headlin corpor tax rate propos tax cut
job act lower current
assumpt howev mani revenue-rel part
tax reform bill scale back initi propos
exampl latest bill allow partial deduct
mortgag interest properti tax alter
mean current bill would like rais feder debt level
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mani initi project attain vote
spend hawk aggress bill may
scale back overal corpor tax rate remain
key lever negoti effect tax rate truli
determin competit rel
countri industri group certainli push keep
tax credit extent credit lower effect
tax rate modestli higher headlin rate keep
competit countri
outsid overal corpor tax rate bill
refin corpor deduct similar unifi
framework releas septemb bill propos full
expens capit expenditur see
smart maneuv front-end econom stimulu
reduc overal drag tax revenu rel
initi propos interest expens deduct
flesh cap amount busi interest
incom plu adjust taxabl incom
simultan lenient restrict
anticip previous thought full
expens capit expenditur would coupl
complet elimin interest expens
deduct thu believ corpor would
elect either interest expens deduct
expens capit expenditur compani get
bit bill straddl middl ground
compani receiv short-term tax benefit
expens capit expenditur subject
restrict interest expens deduct said
limit interest expens deduct mainli affect
net-operating-loss-us rule foreign earn
gener deduct larg anticip net
oper loss carri forward indefinit
increas growth factor gener maintain
valu face inflat yearli limit
slightli
taxabl incom repatri foreign earn
larg tax though byzantin
except deem repatri tax current foreign
foreign earn held cash
equival reinvest foreign earn
foreign earn held cash equival bill
broadli elimin corpor tax deduct credit
section domest product deduct
elimin along mani deduct credit
includ benefit relat orphan drug research mani
energi credit opinion key determin
success tax reform abil sell tax reform
packag whole legisl busi
commun even industry-specif deduct credit
elimin
view tax reform process pleas read
tax reform
 post solid lift robust drug sale
johnson johnson report third-quart result
exceed consensu expect
dont expect major chang fair valu estim
share continu look slightli overvalu despit
strong gain drug group consum devic
divis gain oper weak
consum devic suggest weaken
compani moat especi brand power babi
oral care line nevertheless major
remain busi line perform well still
view compani wide moat intact
drug group post solid oper growth
includ acquisit expect headwind
emerg immunolog drug remicad face two
biosimilar despit success bundl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
price strategi expect aggress price
discount biosimilar lead declin
remicad sale addit gener competit
cancer drug zytiga hiv drug prezista like begin
combin gener competit
lead loss billion current sale
next five year howev expect loss
off-set continu strong growth cancer drug
darzalex quarter imbruvica
along new pipelin drug new drug
mitig gener pressur expect drug group
growth moder current level
consum devic side growth stagnat
consum group face increas pressur on-line
distribut expect increas invest
consum brand help segment achiev
annual growth devic diabet weak
continu expect divest unit
overal restructur effort across devic group
new product launch drive growth toward
annual
blueprint corpor tax rate white hous
outlin anticip adjust framework
especi detail fill continu believ
tax reform trump administr
like occur tax reform assumpt
weve incorpor valuat reason
approxim tax reform ultim look like
therefor dont plan make chang
econom moat rate fair valu estim due
one guid principl think plausibl
tax reform look like close deficit-neutr
take account econom growth stimul tax
reform unifi framework look similar hous
republican blueprint except includ border
adjust tax estim rais approxim
trillion revenu without border adjust tax
framework would like lead materi increas
public debt one largest lever congress could
pull make framework closer revenu neutral would
lower corpor tax rate
assum instead framework
like tax reform plan unifi
framework start point negoti
current view unifi framework tax reform
releas trump administr hous committe
way mean senat committe financ
sept start point tax reform negoti
truli repres eventu tax
reform bill may look like framework similar
guid principl document tax reform like
hous republican better way blueprint
outlin white hous remind item
previous releas guidelin appear fallen
waysid border adjust tax
area framework least partli differ
tax reform assumpt seen report
accomplish trump ideolog tax reform
move territori tax system specif
mention tax credit permut treatment
net
interest expens expens capit
expenditur move territori tax system
compani tax jurisdict gener
earn world-wide tax system like unit
state compani tax
earn foreign earn repatri
dramat chang tax system arguabl could bog
tax reform discuss member congress
like want someth done midterm elect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
season valuat point view move territori
system shouldnt materi affect fair valu estim
mani compani perman reinvest foreign
earn avoid pay tax earn note
open question complet territori tax
system also mention way still tax foreign
profit multi-national corpor reduc rate
framework adjust prior guidelin
partli fall revenu raiser categori
previous releas guidelin outlook includ
assumpt reduc elimin certain special
interest tax provis corpor section
domest product activ deduct
commonli cite earmark elimin
research develop credit mention
preserv framework also state low-incom
hous credit seen align polici goal
preserv
assum manufactur capit
expenditur would allow fulli immedi
expens compani elect also give net
interest expens deduct framework propos
allow full immedi expens new invest
depreci asset least five year limit
net interest expens c-corpor full
expens depreci asset five year
interest idea serv least two main purpos
first sunset full expens help budget
neutral aspect tax reform pass via budget
reconcili procedur second full expens
first five year tax reform enact front load
relat econom stimulu cap amount net
interest expens corpor help rais revenu
could controversi includ final bill
penal compani use lot debt capit
bayer post strong xarelto data lead increas
fair valu estim aug
bayer report excel cardiovascular data xarelto
increas peak sale drug
report bayer eur billion eur billion
increas bayer fair valu estim continu
view stock under-valued also news
posit johnson johnson hold partial right
drug higher peak sale number doesnt
materi alter fair valu estim firm
howev firm posit data reinforc
competit posit econom moat
compass studi coronari peripher arteri
diseas cad pad xarelto combin aspirin
reduc rate cardiovascular death stroke
mace composit primari
endpoint compar aspirin alon
statist signific outcom p-valu less
data particularli strong look context
class drug target mace differ
patient group includ strong data statin
mace improv effect drug
low improv effect
drug mid-teen improv expect
strong efficaci compass lead guidelin
chang treat cad pad despit increas
bleed rate seen studi sinc bleed rate
gener fatal dont expect side effect
significantli limit usag drug
aggreg bayer estim world-wide patient
could benefit cad pad label expans
million line estim howev
estim develop world patient size closer
million project xarelto gain traction
million cad pad patient recent restrict
access drug novarti entresto temper
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market share penetr estim despit strong data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
